Latest Clinical Trials
Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody Shanghai Zhongshan Hospital NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors Wigen Biomedicine Technology (Shanghai) Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma Shanghai Junshi Bioscience Co., Ltd. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) Zai Lab (Shanghai) Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants Shanghai WD Pharmaceutical Co., Ltd. NA
COMPLETED
(Sep 1, 2026)
PHASE1 Phase 2 Clinical Study of MWX203 Injection Alone or in Combination With Inclisiran Sodium Injection in Patients With Mixed Dyslipidemia Shanghai Minwei Biotechnology Co., Ltd NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Shanghai Junshi Bioscience Co., Ltd. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 Abiraterone With Dalpiciclib in Salivary Gland Carcinoma Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients Shanghai Henlius Biotech NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations Shanghai Zhongshan Hospital NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy Mabwell (Shanghai) Bioscience Co., Ltd. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation Shanghai Jeyou Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC Shanghai Zhongshan Hospital NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions Shanghai WD Pharmaceutical Co., Ltd. NA
COMPLETED
(Aug 1, 2026)
PHASE1 A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With Achondroplasia Visen Pharmaceuticals (Shanghai) Co., Ltd. NA
COMPLETED
(Aug 1, 2026)
PHASE2 A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors Shanghai Junshi Bioscience Co., Ltd. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer Shanghai Changzheng Hospital NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC Shanghai Zhongshan Hospital NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors Shanghai Junshi Bioscience Co., Ltd. NA
COMPLETED
(Aug 1, 2026)
PHASE1, PHASE2 A Study of GC101 TIL in Advanced Melanoma Shanghai Juncell Therapeutics NA
RECRUITING
(Aug 1, 2026)
PHASE2 Tigulixostat (IBI128) vs Febuxostat in Gout Innovent Biologics Technology Limited (Shanghai R&D Center) NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 IASO-782 in Systemic Lupus Erythematosus Shanghai IASO Biotechnology Co., Ltd NA
RECRUITING
(Aug 1, 2026)
PHASE1 A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation Genfleet Therapeutics (Shanghai) Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Clinical Trial to Evaluate the Efficacy and Safety of HL-1186 Tablet in the Treatment of Postherpetic Neuralgia Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE2 Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML Shanghai Jiao Tong University School of Medicine NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma Shanghai East Hospital NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC Shanghai Jiao Tong University School of Medicine NA
RECRUITING
(Aug 1, 2026)
PHASE3 CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer Shanghai Changzheng Hospital NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus Shanghai Minwei Biotechnology Co., Ltd NA
RECRUITING
(Aug 1, 2026)
PHASE2 Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma Shanghai Xin Huanghe Pharmaceutical Co., Ltd. NA
COMPLETED
(Aug 1, 2026)
PHASE2 Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC Shanghai Junshi Bioscience Co., Ltd. NA
COMPLETED
(Jul 1, 2026)
PHASE3 A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma Shanghai Junshi Bioscience Co., Ltd. NA
WITHDRAWN
(Jul 1, 2026)
PHASE3 PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Shanghai Junshi Bioscience Co., Ltd. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma Shanghai Junshi Bioscience Co., Ltd. NA
COMPLETED
(Jul 1, 2026)
PHASE1 JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC Shanghai Junshi Bioscience Co., Ltd. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC Shanghai Junshi Bioscience Co., Ltd. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial Shanghai Pudong Hospital NA
RECRUITING
(Jul 1, 2026)
PHASE2 Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine NA
RECRUITING
(Jul 1, 2026)
PHASE2 HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer Shanghai Changzheng Hospital NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation Genfleet Therapeutics (Shanghai) Inc. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Orthopedic Surgery Shanghai Huilun Pharmaceutical Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Abdominal Surgery Shanghai Huilun Pharmaceutical Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis Shanghai Ark Biopharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE3 Response-adapted Luvometinib With or Without Cytarabine in Langerhans Cell Histiocytosis Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Shanghai General Hospital, China NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer Shanghai Zhongshan Hospital NA
RECRUITING
(Jul 1, 2026)
PHASE2 Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma Shanghai Zhongshan Hospital NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial) Shanghai Jiao Tong University School of Medicine NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University NA
COMPLETED
(Jun 1, 2026)
PHASE2 A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma Shanghai 6th People's Hospital NA
SUSPENDED
(Jun 1, 2026)
PHASE2 Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects Shanghai Ark Biopharmaceutical Co., Ltd. NA
COMPLETED
(Jun 1, 2026)
PHASE1 Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University NA
RECRUITING
(Jun 1, 2026)
PHASE2 A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy Shanghai Chest Hospital NA
RECRUITING
(Jun 1, 2026)
PHASE2 Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer Genfleet Therapeutics (Shanghai) Inc. NA
RECRUITING
(Jun 1, 2026)
PHASE3 A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus Shanghai Jiao Tong University School of Medicine NA
RECRUITING
(Jun 1, 2026)
PHASE2 A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma Shanghai 6th People's Hospital NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Becotatug Vedotin Combined With Pucotenlimab for Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University NA
RECRUITING
(Jun 1, 2026)
PHASE2 Combination of CXD and Restrictive Ketogenic Diet Against MASLD Shanghai Municipal Hospital of Traditional Chinese Medicine NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 A Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion Shanghai Jeyou Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer Shanghai EpimAb Biotherapeutics Co., Ltd. NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE1 KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS Syndrome Shanghai Changzheng Hospital NA
RECRUITING
(Jun 1, 2026)
PHASE2 Efficacy and Safety of Paclitaxel Polymeric Micelles in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University NA
RECRUITING
(Jun 1, 2026)
PHASE2 SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer Shanghai Chest Hospital NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2, PHASE3 HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma Shanghai Zhongshan Hospital NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors Shanghai Henlius Biotech NA
ENROLLING BY INVITATION
(May 1, 2026)
PHASE1 A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b Shanghai Vitalgen BioPharma Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE1 Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH) Shanghai Chest Hospital NA
RECRUITING
(May 1, 2026)
PHASE3 A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors Shanghai Hengrui Pharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 IASO-782 in Autoimmune Hematological Diseases Shanghai IASO Biotechnology Co., Ltd NA
RECRUITING
(May 1, 2026)
PHASE1 SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Shanghai Hengrui Pharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE3 A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC Shanghai Henlius Biotech NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy Shanghai Junshi Bioscience Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE2 A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) Lesions Shanghai Shengdi Pharmaceutical Co., Ltd NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE3 A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer Shanghai Henlius Biotech NA
RECRUITING
(May 1, 2026)
PHASE2, PHASE3 A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer Shanghai Henlius Biotech NA
NOT YET RECRUITING
(May 1, 2026)
PHASE1 Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants. Shanghai Allink Biotherapeutics Co., Ltd. NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC. Shanghai Pulmonary Hospital, Shanghai, China NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 A Phase III Study of SYHA1813 for Recurrent or Progressive High-Grade Meningiomas Shanghai Runshi Pharmaceutical Technology Co., Ltd NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer Shanghai Zhongshan Hospital NA
RECRUITING
(May 1, 2026)
PHASE1 A Study of IMM0306 in IgG4-Related Disease ImmuneOnco Biopharmaceuticals (Shanghai) Inc. NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2, PHASE3 Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment Shanghai Junshi Bioscience Co., Ltd. NA
COMPLETED
(Apr 1, 2026)
PHASE3 A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy Shanghai Children's Medical Center NA
RECRUITING
(Apr 1, 2026)
PHASE3 Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer Shanghai Pulmonary Hospital, Shanghai, China NA
COMPLETED
(Apr 1, 2026)
PHASE2, PHASE3 Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma Shanghai Junshi Bioscience Co., Ltd. NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. Shanghai Jiaolian Drug Research and Development Co., Ltd NA
RECRUITING
(Apr 1, 2026)
PHASE2 Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia Shanghai Jiao Tong University School of Medicine NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors Shanghai NK Cell Technology Co., LTD NA
RECRUITING
(Apr 1, 2026)
PHASE1 JS207 Combination Therapy in Triple-negative Breast Cancer Shanghai Junshi Bioscience Co., Ltd. NA
RECRUITING
(Apr 1, 2026)
PHASE2 A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer Shanghai Shengdi Pharmaceutical Co., Ltd NA
RECRUITING
(Apr 1, 2026)
PHASE3 A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions Shanghai Shengdi Pharmaceutical Co., Ltd NA
RECRUITING
(Apr 1, 2026)
PHASE3 Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University NA
RECRUITING
(Apr 1, 2026)
PHASE3 VAH vs VA in Newly Diagnosed Elderly AML Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE3 JS212 Combination Therapies in Metastatic Colorectal Cancer Shanghai Junshi Bioscience Co., Ltd. NA
RECRUITING
(Apr 1, 2026)
PHASE2 Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer Shanghai Shengdi Pharmaceutical Co., Ltd NA
RECRUITING
(Apr 1, 2026)
PHASE3 SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer Shanghai Zhongshan Hospital NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma Shanghai Jiao Tong University School of Medicine NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma Shanghai Jiao Tong University School of Medicine NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal Cancer Shanghai Henlius Biotech NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE1 A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer Shanghai JMT-Bio Inc. NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Tiaoshen Anti-cancer Protocol and CBT for Insomnia and Survival in Ovarian Cancer Shanghai Municipal Hospital of Traditional Chinese Medicine NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3 A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer Shanghai Best-Link Bioscience, LLC NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE1 GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer Genfleet Therapeutics (Shanghai) Inc. NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer Mabwell (Shanghai) Bioscience Co., Ltd. NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE3 Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine NA
RECRUITING
(Apr 1, 2026)
PHASE2 Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma Shanghai Zhongshan Hospital NA
RECRUITING
(Apr 1, 2026)
PHASE2 Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients Shanghai Chest Hospital NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation Shanghai Jiao Tong University School of Medicine NA
RECRUITING
(Mar 1, 2026)
PHASE3 A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer Shanghai Henlius Biotech NA
RECRUITING
(Mar 1, 2026)
PHASE2, PHASE3 ctDNA in HER2+ EBC Neoadjuvant Treatment Shanghai Jiao Tong University School of Medicine NA
RECRUITING
(Mar 1, 2026)
PHASE2 A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer Shanghai JMT-Bio Inc. NA
RECRUITING
(Mar 1, 2026)
PHASE3 Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd NA
WITHDRAWN
(Mar 1, 2026)
PHASE1 A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors Mabwell (Shanghai) Bioscience Co., Ltd. NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor Shanghai Henlius Biotech NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE1 Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia Shanghai Jiao Tong University School of Medicine NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients Shanghai Pulmonary Hospital, Shanghai, China NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma Shanghai Zhongshan Hospital NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 
